- Home
- ESCA vs INBX Comparison
ESCA vs INBX Comparison
Compare ESCA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESCA
- INBX
- Stock Information
- Founded
- ESCA 1922
- INBX 2010
- Country
- ESCA United States
- INBX United States
- Employees
- ESCA N/A
- INBX 161
- Industry
- ESCA Recreational Games/Products/Toys
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ESCA Consumer Discretionary
- INBX Health Care
- Exchange
- ESCA Nasdaq
- INBX Nasdaq
- Market Cap
- ESCA 209.5M
- INBX 168.1M
- IPO Year
- ESCA N/A
- INBX 2020
- Fundamental
- Price
- ESCA $14.81
- INBX $11.47
- Analyst Decision
- ESCA
- INBX Hold
- Analyst Count
- ESCA 0
- INBX 1
- Target Price
- ESCA N/A
- INBX N/A
- AVG Volume (30 Days)
- ESCA 22.4K
- INBX 144.3K
- Earning Date
- ESCA 04-28-2025
- INBX 05-08-2025
- Dividend Yield
- ESCA 4.05%
- INBX 7.40%
- EPS Growth
- ESCA 30.99
- INBX N/A
- EPS
- ESCA 0.93
- INBX 112.62
- Revenue
- ESCA $251,510,000.00
- INBX $200,000.00
- Revenue This Year
- ESCA N/A
- INBX N/A
- Revenue Next Year
- ESCA N/A
- INBX N/A
- P/E Ratio
- ESCA $15.92
- INBX $0.10
- Revenue Growth
- ESCA N/A
- INBX N/A
- 52 Week Low
- ESCA $12.34
- INBX $10.80
- 52 Week High
- ESCA $16.99
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- ESCA 47.37
- INBX 34.68
- Support Level
- ESCA $14.50
- INBX $10.81
- Resistance Level
- ESCA $15.70
- INBX $12.06
- Average True Range (ATR)
- ESCA 0.98
- INBX 1.00
- MACD
- ESCA -0.07
- INBX -0.19
- Stochastic Oscillator
- ESCA 24.57
- INBX 18.52
About ESCA Escalade Incorporated
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.